Table 1.

Class I MHC-restricted vaccine (12MP) trial protocols for patients with high-risk melanoma

Trial	Peptide	Adjuvant	N	Gender, M	Age, <64 years	IR+ (%)
Mel43a	12MP; tetanus	IFA+ GM-CSF	58	37	47	20 (34)
		IFA	60	45	46	44 (73)
Mel44a	12MP; tetanus	IFA ± cyclophos	82	53	57	58 (71)
	12MP:6MHP	IFA ± cyclophos	85	59	64	18 (21)
Mel48a,b	12MP; tetanus	IFA	42	30	35	20 (48)
Total			327c	M 224	<64 years 249	+ (49)
				F 103	≥64 years 78	− (51)

MHC major histocompatibility complex, 12MP 12 class I MHC-restricted melanoma peptides, IFA incomplete Freund’s adjuvant, GM-CSF granulocyte–macrophage colony-stimulating factor, 6MHP 6 class II MHC-restricted melanoma helper peptides, IR immune response

^aTen vaccinations were administered for Mel43 and Mel44 and 6 for Mel48

^bPatients with nonmeasurable disease or equivocal findings may be enrolled in Mel48

^cOne participant belonged to both trials 43 and 48